- Home »
- Quarterly Results »
- Caplin Point Laboratories Q1 Results, 16.1% Revenue Growth and 19.8% PAT Increase
Caplin Point Laboratories Q1 Results, 16.1% Revenue Growth and 19.8% PAT Increase
Caplin Point Laboratories Q1 Results: Revenue grew by 16.1% to ₹458.96 crores, and PAT increased by 19.8% to ₹124.92 crores, reflecting strong market expansion and cost management.
by P Nandhini
Updated Aug 07, 2024
Table of Content
Caplin Point Laboratories has reported strong financial results for the first quarter of FY25. The company saw its revenue from operations reach ₹458.96 crores, marking a 16.1% increase compared to the same period last year.
This growth reflects the company's successful expansion in key markets like Latin America and the US. Additionally, the company's profit after tax (PAT) rose to ₹124.92 crores, a 19.8% year-over-year increase, highlighting its improving profitability and efficiency.
The company's gross profit margin also improved to 59.6%, up from 55.3% in the previous year. This boost in profitability is partly due to new product launches and effective cost management.
Caplin Point's cash reserves remain strong, with free cash reserves at ₹969.2 crores, and total liquid assets amounting to ₹1,849 crores. Overall, these results demonstrate Caplin Point's continued growth and solid financial health.
Caplin Point Laboratories Q1 Results
Caplin Point Laboratories has reported its financial results for the first quarter of FY25, showing significant growth in revenue and profitability. The company's strategic expansion and cost management have contributed to its strong performance. Below is a summary of the key financial metrics:
| Metric | Q1 FY25 | Q1 FY24 | Year-over-Year Change |
|---|---|---|---|
| Revenue from Operations | ₹458.96 crores | ₹395.28 crores | +16.1% |
| Other Income | ₹10.56 crores | ₹8.32 crores | +26.9% |
| Total Revenue | ₹469.52 crores | ₹403.60 crores | +16.3% |
| Total Expenses | ₹305.84 crores | ₹267.75 crores | +14.2% |
| EBITDA | ₹163.68 crores | ₹135.85 crores | +20.5% |
| EBITDA Margin | 35.4% | 33.6% | +1.8 percentage points |
| Depreciation and Amortization | ₹12.34 crores | ₹10.78 crores | +14.5% |
| Profit Before Tax (PBT) | ₹151.34 crores | ₹125.07 crores | +21.0% |
| Tax Expense | ₹26.42 crores | ₹20.82 crores | +26.9% |
| Profit After Tax (PAT) | ₹124.92 crores | ₹104.25 crores | +19.8% |
| Gross Profit Margin | 59.6% | 55.3% | +4.3 percentage points |
| Free Cash Reserves | ₹969.2 crores | Not provided | - |
| Total Liquid Assets | ₹1,849 crores | Not provided | - |
Please Click Here
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an Indian pharmaceutical company that manufactures and markets a wide range of medicines. It is known for producing affordable generic drugs and exporting them to various countries, especially in Latin America and Africa.
The company focuses on providing high-quality healthcare products, including injectables, tablets, capsules, and ointments. Caplin Point has a strong emphasis on research and development to create innovative solutions for healthcare needs.
It is headquartered in Chennai and continues to grow its presence in the global pharmaceutical market.
Caplin Point Laboratories Q1 Results 2024 - FAQs
1. What was Caplin Point Laboratories' revenue from operations in Q1 FY25?
In Q1 FY25, Caplin Point Laboratories achieved a revenue from operations of ₹458.96 crores, reflecting a 16.1% increase compared to the same quarter last year.
2. How much did Caplin Point’s profit after tax (PAT) increase in Q1 FY25?
PAT increased by 19.8% to ₹124.92 crores.
3. What is the gross profit margin for Caplin Point in Q1 FY25?
The gross profit margin is 59.6%.
4. How did Caplin Point’s total revenue change in Q1 FY25?
Total revenue increased by 16.3% to ₹469.52 crores.
5. What were Caplin Point’s free cash reserves in Q1 FY25?
Free cash reserves were ₹969.2 crores.
6. How much did EBITDA increase in Q1 FY25?
EBITDA increased by 20.5% to ₹163.68 crores.
7. What was the EBITDA margin in Q1 FY25?
The EBITDA margin was 35.4%.
8. What was the increase in total expenses in Q1 FY25?
Total expenses increased by 14.2% to ₹305.84 crores.
9. Where is Caplin Point Laboratories headquartered?
Caplin Point Laboratories is headquartered in Chennai.
10. What was Caplin Point’s performance in terms of research and development?
Caplin Point emphasizes R&D in creating innovative healthcare solutions.